DUBLIN–(BUSINESS WIRE)–The “Research Report on China’s Exemestane Market, 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
According to the publisher’s market research, Pharmacia & Upjoin’s exemestane was not introduced into the Chinese market until 2008, when several generic drugs from local Chinese companies were already available in the Chinese market, of which the exemestane tablets from Qilu Pharmaceutical was already marketed in China in 2002.
Pharmacia &Upjoin’s exemestane (trade name AROMASIN) is extremely competitive in the Chinese market, accounting for more than 90% of China’s exemestane market in 2020 in terms of sales value.
Despite the impact of the COVID-19 outbreak on the Chinese healthcare industry in early 2020, the sales value of exemestane in the Chinese market continued to grow in 2020, reaching approximately CNY400 million (USD61.6 million), with a CAGR of 9.2% from 2016 to 2020.
Breast cancer has replaced lung cancer as the number one cancer worldwide due to the rapid growth in the number of new cases in 2020. The increasing breast cancer cases are fundamentally caused by the altering risk factors for breast cancer, such as changing lifestyles and notions of marriage and childbearing due to economic growth, namely a general rise in the age of women having children, a decrease in the average number of births, overweight, obesity and lack of exercise, all contributing to the increase in the incidence of breast cancer.
The publisher expects that from 2021 to 2025, new cases of breast cancer in China will continue to grow, resulting in increases in both sales volume and value of exemestane in the Chinese market.
Topics Covered:
- Impact of COVID-19 on China’s Exemestane Market
- Development Environment of Exemestane in China
- Sales Volume of Exemestane in China
- Sales Volume and Value of Exemestane in China by Region
- Major Exemestane Manufacturers in China and Their Market Shares
- Sales Price of Exemestane in China
- Prospects of China’s Exemestane Market, 2021-2025
Key Topics Covered:
1 Relevant Concepts of Exemestane
1.1 Indications of Exemestane
1.2 Development of China’s Exemestane Market
1.3 Governmental Approval of Exemestane in China
1.4 The Impact of COVID-19 on China’s Exemestane Market
2 Sales of Exemestane in China, 2016-2020
2.1 Sales Value
2.1.1 Sales Value in China
2.1.2 Sales Value in China by Region
2.2 Sales Volume
2.2.1 Sales Volume in China
2.2.2 Sales Volume in China by Region
2.3 Sales of Exemestane in China by Dosage Form, 2016-2020
2.3.1 Tablets
2.3.2 Capsules
3 Analysis of Major Exemestane Manufacturers in China, 2020
3.1 Analysis of Market Share
3.1.1 Market Share of Manufacturers by Sales Value
3.1.2 Market Share of Manufacturers by Sales Volume
3.2 Pharmacia & Upjohn SpA
3.2.1 Company Profile
3.2.2 Sales of Exemestane in China
3.3 Qilu Pharmaceutical Co., Ltd.
3.3.1 Company Profile
3.3.2 Sales of Exemestane in China
3.4 Hainan Tongyong Tongmeng Pharmaceutical Co., Ltd.
3.4.1 Company Profile
3.4.2 Sales of Exemestane in China
3.5 Tongfang Pharmaceutical Group Co., Ltd.
3.5.1 Company Profile
3.5.2 Sales of Exemestane in China
4 Sales Price of Exemestane of Different Companies in China, 2020-2021
4.1 Pharmacia & Upjohn SpA (AROMASIN)
4.2 Qilu Pharmaceutical Co., Ltd. (SuLai)
4.3 Hainan Tongyong Tongmeng Pharmaceutical Co., Ltd. (YiSiTan)
4.4 Tongfang Pharmaceutical Group Co., Ltd. (YouKeYi)
5 Prospects of China’s Exemestane Market, 2021-2025
5.1 Influencing Factors for the Market Development
5.1.1 The Impact of COVID-19 on the Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/r/mcr0j0